AI-driven Quality Control of cell-based ATMPs: Automated, Accurate, and Affordable
(2026) In Cytotherapy- Abstract
- The production of neuroepithelial stem (NES) cells, a promising therapeutic candidate for neurological conditions such as stroke and spinal cord injuries, faces significant manufacturing challenges, particularly in quality control (QC). Specifically, current QC methods rely on labor-intensive manual assessments that are costly, time-consuming, and subject to operator bias, limiting scalability and reproducibility. This study addresses these limitations by developing a Convolutional Neural Network (CNN)-based model for automating morphological QC during NES cell expansion. The model achieved an area under the receiver operating characteristic curve (AUROC) of > 0.997 when applied to test data, with robustness validated via image rotation... (More)
- The production of neuroepithelial stem (NES) cells, a promising therapeutic candidate for neurological conditions such as stroke and spinal cord injuries, faces significant manufacturing challenges, particularly in quality control (QC). Specifically, current QC methods rely on labor-intensive manual assessments that are costly, time-consuming, and subject to operator bias, limiting scalability and reproducibility. This study addresses these limitations by developing a Convolutional Neural Network (CNN)-based model for automating morphological QC during NES cell expansion. The model achieved an area under the receiver operating characteristic curve (AUROC) of > 0.997 when applied to test data, with robustness validated via image rotation and segmentation. The model successfully distinguished key morphological features, such as rosette-like structures in high-quality cultures, and detected pronounced heterogeneity in low-quality samples. Complementary flow cytometry validation confirmed the biological relevance of the model’s predictions. By integrating this CNN-based QC system, we offer a scalable and cost-effective solution for real-time monitoring, batch consistency, and reduced process variability. This approach supports the clinical translation of NES cell therapies and holds broader applicability across other cell-based advanced therapy medicinal products. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/92c77c86-b8a2-4a07-92aa-5f2c23292e94
- author
- Magnusson, Rasmus
; Hägg, Alice
LU
; Twohig, Daniel
LU
; Savchenko, Ekaterina
LU
; Ghosheh, Nidal
; Melguizo-Sanchis, Dario
; Falk, Anna
LU
and Synnergren, Jane
- organization
- publishing date
- 2026-02-01
- type
- Contribution to journal
- publication status
- epub
- subject
- in
- Cytotherapy
- article number
- 102135
- publisher
- Taylor & Francis
- ISSN
- 1477-2566
- DOI
- 10.1016/j.jcyt.2026.102135
- language
- English
- LU publication?
- yes
- id
- 92c77c86-b8a2-4a07-92aa-5f2c23292e94
- date added to LUP
- 2026-03-19 13:22:30
- date last changed
- 2026-03-19 13:39:04
@article{92c77c86-b8a2-4a07-92aa-5f2c23292e94,
abstract = {{The production of neuroepithelial stem (NES) cells, a promising therapeutic candidate for neurological conditions such as stroke and spinal cord injuries, faces significant manufacturing challenges, particularly in quality control (QC). Specifically, current QC methods rely on labor-intensive manual assessments that are costly, time-consuming, and subject to operator bias, limiting scalability and reproducibility. This study addresses these limitations by developing a Convolutional Neural Network (CNN)-based model for automating morphological QC during NES cell expansion. The model achieved an area under the receiver operating characteristic curve (AUROC) of > 0.997 when applied to test data, with robustness validated via image rotation and segmentation. The model successfully distinguished key morphological features, such as rosette-like structures in high-quality cultures, and detected pronounced heterogeneity in low-quality samples. Complementary flow cytometry validation confirmed the biological relevance of the model’s predictions. By integrating this CNN-based QC system, we offer a scalable and cost-effective solution for real-time monitoring, batch consistency, and reduced process variability. This approach supports the clinical translation of NES cell therapies and holds broader applicability across other cell-based advanced therapy medicinal products.}},
author = {{Magnusson, Rasmus and Hägg, Alice and Twohig, Daniel and Savchenko, Ekaterina and Ghosheh, Nidal and Melguizo-Sanchis, Dario and Falk, Anna and Synnergren, Jane}},
issn = {{1477-2566}},
language = {{eng}},
month = {{02}},
publisher = {{Taylor & Francis}},
series = {{Cytotherapy}},
title = {{AI-driven Quality Control of cell-based ATMPs: Automated, Accurate, and Affordable}},
url = {{http://dx.doi.org/10.1016/j.jcyt.2026.102135}},
doi = {{10.1016/j.jcyt.2026.102135}},
year = {{2026}},
}